Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Puretech Health Plc ADR (PRTC)

Puretech Health Plc ADR (PRTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 359,136
  • Shares Outstanding, K 24,168
  • Annual Sales, $ 4,830 K
  • Annual Income, $ 27,780 K
  • EBIT $ 0 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.07
  • Price/Sales 58.12
  • Price/Cash Flow 6.08
  • Price/Book 0.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.50 +3.45%
on 03/30/26
18.00 -16.67%
on 03/06/26
-1.77 (-10.55%)
since 02/27/26
3-Month
14.50 +3.45%
on 03/30/26
19.92 -24.70%
on 01/16/26
-1.64 (-9.86%)
since 12/30/25
52-Week
13.30 +12.78%
on 04/10/25
20.00 -25.00%
on 04/07/25
-4.10 (-21.47%)
since 04/01/25

Most Recent Stories

More News
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Designations provide market exclusivity as well as other development incentives

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech Appoints Robert Lyne as Chief Executive Officer

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy...

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups

PRTC.LN : 110.000 (+1.85%)
PRTC : 15.00 (+0.94%)
Leerink Partners Reaffirms Their Buy Rating on PureTech Health (PRTC)

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on PureTech Health on September 30. The company’s shares closed yesterday at $19.00.Elevate Your Investing Strategy: Take advantage of...

PRTC : 15.00 (+0.94%)

Business Summary

PureTech Health plc is a clinical-stage biotherapeutics company. It engages in discovering, developing and commercializing medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological...

See More

Key Turning Points

3rd Resistance Point 15.29
2nd Resistance Point 15.15
1st Resistance Point 15.07
Last Price 15.00
1st Support Level 14.85
2nd Support Level 14.71
3rd Support Level 14.63

See More

52-Week High 20.00
Fibonacci 61.8% 17.44
Fibonacci 50% 16.65
Fibonacci 38.2% 15.86
Last Price 15.00
52-Week Low 13.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.